"Estrogen Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
| Descriptor ID |
D004965
|
| MeSH Number(s) |
D06.347.295 D27.505.696.399.450.327
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Antagonists".
This graph shows the total number of publications written about "Estrogen Antagonists" by people in this website by year, and whether "Estrogen Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 2 | 1 | 3 |
| 1995 | 4 | 0 | 4 |
| 1996 | 3 | 4 | 7 |
| 1997 | 7 | 5 | 12 |
| 1998 | 5 | 4 | 9 |
| 1999 | 4 | 5 | 9 |
| 2000 | 3 | 3 | 6 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 3 | 4 |
| 2005 | 5 | 1 | 6 |
| 2006 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 2 | 2 |
| 2010 | 2 | 4 | 6 |
| 2011 | 4 | 5 | 9 |
| 2012 | 1 | 2 | 3 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 3 | 5 |
| 2016 | 3 | 3 | 6 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 2 | 3 |
| 2020 | 1 | 2 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Antagonists" by people in Profiles.
-
Making Informed Choices On Incorporating Chemoprevention into carE (MiCHOICE, SWOG 1904): Design and methods of a cluster randomized controlled trial. Contemp Clin Trials. 2024 Jul; 142:107564.
-
Apoptosis-modulatory miR-361-3p as a novel treatment target in endocrine-responsive and endocrine-resistant breast cancer. J Endocrinol. 2023 03 01; 256(3).
-
Elacestrant and the Promise of Oral SERDs. J Clin Oncol. 2022 10 01; 40(28):3227-3229.
-
Converting Men From Clomiphene Citrate to Natesto for Hypogonadism Improves Libido, Maintains Semen Parameters, and Reduces Estradiol. Urology. 2021 02; 148:141-144.
-
The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells. Mol Pharmacol. 2020 07; 98(1):24-37.
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
-
Targeted degradation of activating estrogen receptor a ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 2020 Apr; 180(3):611-622.
-
Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members. Urology. 2020 05; 139:104-109.
-
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. N Engl J Med. 2019 06 20; 380(25):2395-2405.
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.